AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Clinical trial NCT05850234 · RECRUITING

Trial details

NCT number: NCT05850234
Sponsor: AstraZeneca
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Relapsed/Refractory Multiple Myeloma

Start date: 2023-07-20
Primary completion: 2027-10-01
Enrollment: 232

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.